Two labels can describe materially different peptides
CJC-1295 was developed as a growth-hormone-releasing hormone analog with a reactive drug-affinity-complex component designed to form a covalent bond with serum albumin. That albumin-binding design materially changes its persistence compared with shorter-acting GHRH analogs.
Online listings often use ‘CJC-1295 without DAC’ for a different short-acting peptide commonly called modified GRF 1-29. The labels are familiar, but they can hide a real structural distinction.
What the DAC changes
The drug affinity complex is not simply a marketing suffix. In the studied CJC-1295 molecule, the reactive group supports albumin binding, which was intended to extend exposure. Published human studies of CJC-1295 reported prolonged changes in growth hormone and IGF-I measurements after administration.
Those studies characterize a specific investigational molecule. Their pharmacokinetic findings should not be automatically applied to a product that lacks the DAC component.
Where Mod GRF 1-29 fits
Modified GRF 1-29 is a shortened and substituted analog based on the active N-terminal region of GHRH. It is generally discussed as a shorter-acting research peptide and is structurally distinct from albumin-binding CJC-1295.
Calling it ‘CJC-1295 no DAC’ may be commercially convenient, but the label can blur the difference between related research compounds. Sequence-level identification is more reliable than the storefront name.
Why papers and products are easily mismatched
A search for CJC-1295 may return studies of the DAC-containing investigational molecule, while a supplier result with the same headline name may describe Mod GRF 1-29. If the reader looks only at the shared name, the evidence and the product can appear more closely connected than they are.
Match the article’s test material to the product’s sequence, modifications, and expected mass before carrying any result into a procurement or experimental rationale.
What researchers should verify
A complete listing should make the molecular identity understandable without requiring the reader to guess what ‘with’ or ‘without’ means.
- Exact amino-acid sequence
- Presence or absence of the albumin-binding DAC group
- Expected molecular formula and mass
- Whether ‘no DAC’ means Mod GRF 1-29
- Identity result linked to the current lot
What the human studies establish
Early studies in healthy adults showed that the long-acting CJC-1295 construct could alter measured GH and IGF-I profiles for an extended period. These were controlled investigations of pharmacology and short-term observations, not proof for the wide range of outcomes promoted in consumer marketing.
The existence of human research is important, but evidence must still be described by study question, population, material, duration, and endpoint.
A clearer way to document the compound
For PDD comparisons, the most defensible approach is to list ‘CJC-1295 with DAC’ and ‘Mod GRF 1-29 / CJC-1295 without DAC’ as distinct records whenever the supplier documentation supports that distinction.
If the sequence or modification is missing, the listing should be marked unclear rather than assigned to a category by assumption.
Sources and further reading
Primary and standards-based sources used to frame this educational overview:
Explore related resources
Peptide Due Diligence Research Brief
Keep the evidence in view.
Receive concise briefings on analytical testing, documentation quality, supplier transparency, and new additions to the research library.
By subscribing, you agree to receive PDD research emails. Unsubscribe at any time.
Already subscribed? Get your free checklist.